Integra LifeSciences (NASDAQ:IART) Shares Gap Down – Here’s Why

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price gapped down before the market opened on Friday. The stock had previously closed at $16.09, but opened at $13.31. Integra LifeSciences shares last traded at $13.6270, with a volume of 130,662 shares trading hands.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Thursday, June 18th. Wells Fargo & Company boosted their target price on shares of Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. UBS Group began coverage on shares of Integra LifeSciences in a report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price for the company. BMO Capital Markets began coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective for the company. Finally, Truist Financial upgraded Integra LifeSciences to a “hold” rating in a research note on Thursday. One analyst has rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $18.86.

Integra LifeSciences Stock Down 18.7%

The company has a market capitalization of $1.02 billion, a PE ratio of -145.66, a price-to-earnings-growth ratio of 0.84 and a beta of 1.21. The company’s fifty day moving average is $16.83 and its 200-day moving average is $15.17. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.08. The business had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, analysts predict that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IART. Paradigm Capital Management Inc. NY purchased a new stake in Integra LifeSciences in the 2nd quarter worth $61,766,000. Wellington Management Group LLP lifted its position in shares of Integra LifeSciences by 12.4% in the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after acquiring an additional 160,814 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after acquiring an additional 589,408 shares during the period. Invenomic Capital Management LP grew its position in shares of Integra LifeSciences by 78.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after purchasing an additional 463,729 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its stake in Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after purchasing an additional 211,774 shares during the period. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.